 |
|
|
| |
Characterization of Maraviroc Resistance in Patients Failing Treatment with CCR5-Tropic Virus in MOTIVATE 1 and 2
|
| |
| |
Reported by Jules Levin
3rd International Workshop on Targeting HIV Entry
Washington, DC, USA, December 7-8, 2007
Julie Mori1, Marilyn Lewis1, Paul Simpson1, Jeannette Whitcomb2, Lynn McFadyen1, Phylinda Chan1 and Mike Westby1
1Pfizer Global Research and Development, Sandwich, UK; 2Monogram Biosciences, California, USA
Maraviroc Resistance: Author Summary of Clinical Findings
Adequate exposure to maraviroc combined with a lack of active drugs in a patients OBT were the most likely reasons for the development of maraviroc resistance and subsequent treatment failure in four patients failing maraviroc-based therapy with CCR5-tropic virus
--Maraviroc resistance was selected in those patients who had ≦1 active background drug in their treatment regimen
--Maraviroc exposure was at the low end of the optimal exposure distribution
|
| |
|
|
|
|
|
